Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 13Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 6Prostatic Neoplasms 6Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Melanoma 5Testicular Neoplasms 4Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Carcinoma, Transitional Cell 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Teratoma 2Squamous Cell Carcinoma of Head and Neck 2Osteosarcoma 2Optic Nerve Glioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Nasopharyngeal Neoplasms 2Multiple Myeloma 2Kidney Neoplasms 2Hematologic Neoplasms 2Familial ependymoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2

Interventions

pembrolizumab 20atezolizumab 8Nivolumab 8Docetaxel 7Carboplatin 6cemiplimab 5Immune Checkpoint Inhibitors 5Radiotherapy 4Paclitaxel 4Filgrastim 4Drug Therapy 4fludarabine 3durvalumab 3Radiosurgery 3Pemetrexed 3Gemcitabine 3Fluorouracil 3Cyclophosphamide 3Cisplatin 3Cetuximab 3Bortezomib 3niraparib 2motexafin gadolinium 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Tetrahydrouridine 2Taxes 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Oxaliplatin × Genitourinary × Clear all
NCT05704985 2025-05-29

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

Phase 1 Active not recruiting
39 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasms, Pancreatic Neoplasms, Skin Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡